CLNN vs. OCUP, AADI, HCWB, GANX, RMTI, XLO, IMRX, BLRX, NBRV, and SNSE
Should you be buying Clene stock or one of its competitors? The main competitors of Clene include Ocuphire Pharma (OCUP), Aadi Bioscience (AADI), HCW Biologics (HCWB), Gain Therapeutics (GANX), Rockwell Medical (RMTI), Xilio Therapeutics (XLO), Immuneering (IMRX), BioLineRx (BLRX), Nabriva Therapeutics (NBRV), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical preparations" industry.
Clene (NASDAQ:CLNN) and Ocuphire Pharma (NASDAQ:OCUP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking.
Clene has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Ocuphire Pharma has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500.
Ocuphire Pharma has higher revenue and earnings than Clene. Ocuphire Pharma is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ocuphire Pharma had 1 more articles in the media than Clene. MarketBeat recorded 3 mentions for Ocuphire Pharma and 2 mentions for Clene. Ocuphire Pharma's average media sentiment score of 0.22 beat Clene's score of -0.43 indicating that Ocuphire Pharma is being referred to more favorably in the news media.
Clene received 26 more outperform votes than Ocuphire Pharma when rated by MarketBeat users. Likewise, 75.00% of users gave Clene an outperform vote while only 65.96% of users gave Ocuphire Pharma an outperform vote.
23.3% of Clene shares are held by institutional investors. Comparatively, 15.0% of Ocuphire Pharma shares are held by institutional investors. 25.1% of Clene shares are held by company insiders. Comparatively, 8.7% of Ocuphire Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Ocuphire Pharma has a net margin of -52.42% compared to Clene's net margin of -7,569.42%. Ocuphire Pharma's return on equity of -22.30% beat Clene's return on equity.
Clene presently has a consensus price target of $6.50, suggesting a potential upside of 1,560.71%. Ocuphire Pharma has a consensus price target of $19.00, suggesting a potential upside of 879.38%. Given Clene's higher possible upside, research analysts clearly believe Clene is more favorable than Ocuphire Pharma.
Summary
Clene beats Ocuphire Pharma on 9 of the 17 factors compared between the two stocks.
Get Clene News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
